Camurus AB operates as a research based pharmaceutical company. The company is headquartered in Lund, Skane and currently employs 273 full-time employees. The company went IPO on 2015-12-03. The firm has a diversified research portfolio, which includes products in clinical trials. The Company’s products are based on FluidCrystal formulation technology. FluidCrystal is Company's patent-protected technology platform. Camurus AB is the parent company of the Group, which comprises of legal entities, namely: Camurus Inc, Cubosome Inc, Development AB, Camurus GmbH, Camurus Ltd, Camurus Oy, Camurus AS, Camurus SAS, Camurus Pty Ltd, Camurus S.L, Camurus ApS, Camurus BV and Camurus Austria GmbH.
Follow-Up Questions
Camurus AB のCEOは誰ですか？
Mr. Fredrik Tiberg は Camurus AB の Chief Executive Officer で、2002 から在籍しています。
CAMRF の株価パフォーマンスは？
CAMRF の現在の価格は $0 で、最終取引日から 0% decreased 変動しました。
Camurus AB の主な事業テーマや業界は？
Camurus AB は Pharmaceuticals 業界、セクターは Health Care に属しています。
